These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34404436)

  • 1. Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China.
    Chen DG; Chen G; Wang C; Ke LF; Wu H; He HM; Yang Y; Chen YP
    Infect Agent Cancer; 2021 Aug; 16(1):57. PubMed ID: 34404436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
    Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
    Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy.
    Xie W; Zhou D; Hu K; Xiao X; Huang W; He J; Shi J; Luo Y; Zhang J; Lin M; Cai Z; Huang H; Ye X
    Exp Ther Med; 2013 Jul; 6(1):109-114. PubMed ID: 23935730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B surface antigen positivity is associated with poor short- and long-term outcomes in patients with diffuse large B-cell lymphoma who received CHOP or R-CHOP.
    Zhan Z; Guo W; Wan X; Wang B; Li J; Wang H; Li Z; Huang Y; Young KH; Bai O
    Front Immunol; 2024; 15():1324113. PubMed ID: 38318173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma.
    Wang F; Xu RH; Luo HY; Zhang DS; Jiang WQ; Huang HQ; Sun XF; Xia ZJ; Guan ZZ
    BMC Cancer; 2008 Apr; 8():115. PubMed ID: 18433487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin.
    Deng L; Song Y; Young KH; Hu S; Ding N; Song W; Li X; Shi Y; Huang H; Liu W; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Ying Z; Zhang C; Sun Y; Zhu J
    Oncotarget; 2015 Sep; 6(28):25061-73. PubMed ID: 26314957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study.
    Huang HH; Hsiao FY; Chen HM; Wang CY; Ko BS
    Br J Haematol; 2021 Jan; 192(1):110-118. PubMed ID: 33131074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
    Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K
    Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
    Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
    Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
    Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
    Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
    Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
    Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome.
    Guo YF; Pan JX; Zhuang WH
    Infect Agent Cancer; 2018; 13():40. PubMed ID: 30559832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy.
    Guo W; Zhang W; Liu C; Song Y; Bai O
    PLoS One; 2015; 10(6):e0129064. PubMed ID: 26053951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma.
    Liu P; Han Y; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Zhou LQ; Yang JL; Yang S; Wen TY; Shi YK
    Chin Med J (Engl); 2019 Aug; 132(15):1807-1814. PubMed ID: 31335477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
    Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic roles of hepatitis B virus antibody in diffuse large B-cell lymphoma patients.
    Hu S; Chen N; Lu K; Zhen C; Sui X; Fang X; Li Y; Luo Y; Zhou X; Wang X
    Leuk Lymphoma; 2021 Jun; 62(6):1335-1343. PubMed ID: 33399486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.